Regeneron and Teva team up to develop and market pain drug

By John Golden

No Comment

Westchester-based Regeneron Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd., an Israeli producer of generic medicines headquartered in Jerusalem, recently announced a global agreement to develop and commercialize fasinumab, an investigational antibody against nerve growth factor, or NGF, that is in clinical trials by Regeneron as a treatment for osteoarthritis pain and chronic low back pain. Under the…

This content is for Westfair Online members only. Please login to view this content. Become a member by Registering Here. If you would prefer to start with a 12 week free trial, Click Here.


About the author

John Golden
As managing editor of the Business Journals, John Golden directs news coverage of Westchester and Fairfield counties and the Hudson Valley region. He was an award-winning upstate columnist and feature writer before joining the Business Journal in 2007. He is the author of “Northern Drift: Sketches on the New York Frontier,” a collection of his regional journalism.

Related Articles